RxDoctor Payments Data

Jennifer Pound

Nurse Practitioner · Kansas City, MONPI 1881021285

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,877 of the $10,795 with a category attached, or 82.2%. It is spread thinly across 50 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,170 and has fallen 50.0% since, to $1,584 in 2025. Among nurse practitioner clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,795in general payments, 2019–2025

Across 435 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$938
  • Daiichi Sankyo Inc.$635
  • Pfizer$607
  • plus $4K from 44 others

What the payments were for

  • Speaking & faculty fees$1,70016%
  • Travel & lodging$2092%
  • Food & beverage$8,87782%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,795 in reported general payments places this provider in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin23$30,108
EliquisApixaban30$24,143
OzempicSemaglutide16$22,715
JanuviaSitagliptin Phosphate12$18,427
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$6,749
SynthroidLevothyroxine Sodium36$3,008
Atorvastatin Calcium179$1,743
Gabapentin99$1,720
Omeprazole74$1,705
Rosuvastatin Calcium130$1,311
Albuterol Sulfate HfaAlbuterol Sulfate45$1,181
Duloxetine Hcl35$1,140
Levothyroxine Sodium157$1,084
Metoprolol Succinate76$1,001
Nebivolol Hcl12$970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$129$30,10823 claims
PfizerEliquis$607$24,14330 claims
Novo NordiskOzempic$474$22,71516 claims
MerckJanuvia$15$18,42712 claims
AbbVieSynthroid$1,288$3,00836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →